Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization
Modern Pathology2013Vol. 26(12), pp. 1545–1553
Citations Over TimeTop 1% of 2013 papers
Christina Selinger, Toni-Maree Rogers, Prudence A. Russell, Sandra O’Toole, Po Yee Yip, Gavin Wright, Zoe Wainer, Lisa G. Horvath, Michael Boyer, Brian C. McCaughan, Maija R.J. Kohonen‐Corish, Stephen B. Fox, Wendy A. Cooper, Benjamin Solomon
Related Papers
- → ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor(2017)39 cited
- → Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma(2012)31 cited
- → ALK-driven tumors and targeted therapy: focus on crizotinib(2014)28 cited
- → Success of Crizotinib Combined with Whole-Brain Radiotherapy for Brain Metastases in a Patient with Anaplastic Lymphoma Kinase Rearrangement-Positive Non-Small-Cell Lung Cancer(2018)12 cited